Memorial Sloan Kettering Cancer Center, Leukemia Service, New York, NY 10065, USA.
Int J Hematol. 2012 Aug;96(2):164-70. doi: 10.1007/s12185-012-1121-y. Epub 2012 Jul 13.
Inducing a complete remission (CR) in patients with acute myeloid leukemia is a prerequisite to long-term disease control with subsequent post-remission consolidation chemotherapy or allogeneic hematopoietic stem cell transplantation. The use of 7 days of infusional cytarabine and 3 days of daunorubicin or idarubicin (7 + 3) has become the standard of care to induce CR, based on clinical trials conducted in the 1980s. Efforts to improve on the CR rate seen with the 7 + 3 regimen that translates into better overall patient survival have been disappointing. Here we review recent phase III studies of novel induction strategies that show promise in increasing the rate of CR and improving disease outcome.
在急性髓系白血病患者中诱导完全缓解（CR）是长期疾病控制的前提，随后进行缓解后巩固化疗或异基因造血干细胞移植。基于 20 世纪 80 年代进行的临床试验，使用 7 天输注阿糖胞苷和 3 天柔红霉素或伊达比星（7+3）已成为诱导 CR 的标准治疗方法。尽管人们努力提高 7+3 方案的 CR 率，从而提高整体患者生存率，但结果令人失望。在这里，我们回顾了最近的 III 期新型诱导策略研究，这些研究显示出提高 CR 率和改善疾病结局的潜力。
